New HIV drug said to show promise

A new way of treating HIV could be on the way, says drug developer Biotron. On Tuesday it released preliminary results of an early trial of its lead anti-viral drug, BIT225, on 21 HIV-infected patients in Thailand. "The results suggest that BIT225 is a candidate agent that could be useful in future eradication strategies," Biotron managing director Michelle Miller said.

A new way of treating HIV could be on the way, says drug developer Biotron. On Tuesday it released preliminary results of an early trial of its lead anti-viral drug, BIT225, on 21 HIV-infected patients in Thailand. "The results suggest that BIT225 is a candidate agent that could be useful in future eradication strategies," Biotron managing director Michelle Miller said.

Anti-HIV drugs target the virus in T-cells and aim to keep the virus in check and ensure the number of T-cells stays at a healthy level. But these drugs do not target "reservoirs" of HIV that exist in other cells, and which act as continuing sources of infection.

"Existing drugs clear that up [the T-cell infection], but they don't ever clear up this underlying reservoir," Dr Miller said. She said Biotron's drug worked against the underlying HIV reservoir.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles